Modification and biological evaluation of novel 4-hydroxy-pyrone derivatives as non-peptidic HIV-1 protease inhibitors

Medicinal Chemistry Research

Volumn 20, Issue 2, 2011, Pages 200-209

  He, Meizi ^a   Yang, Ning ^a   Sun, Chunlai ^a   Yao, Xiaojian ^b   Yang, Ming ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

4 Hydroxy pyran 2 ones; Anti SIV activity; HIV 1 protease inhibitors

Indexed keywords

3 (2 CHLOROPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2 CHLOROPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2 CHLOROPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; 3 (2 ETHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2 ETHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2 ETHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; 3 (2 TOLYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2 TOLYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2 TOLYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; 3 (2,5 DIETHOXYPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2,5 DIETHOXYPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2,5 DIETHOXYPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; 3 (2,5 DIMETHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2,5 DIMETHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (2,5 DIMETHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; 3 (BENZYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (BENZYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYLPYRAN 2 ONE; 3 (BENZYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; 4 HYDROXYPYRONE DERIVATIVE; 4 PYRONE DERIVATIVE; 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 1 YLOXY)METHYL] 6 PHENYL 3 (PHENYLTHIO)PYRAN 2 ONE; 5,6 DIHYDRO 4 HYDROXY 6 [(NAPHTHALEN 2 YLOXY)METHYL] 6 PHENYL 3 (PHENYLTHIO)PYRAN 2 ONE; 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 3 (PHENYLTHIO) 6 [(PHENYLTHIO)METHYL]PYRAN 2 ONE; FUNCTIONAL GROUP; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 79952709090     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-010-9307-4     Document Type: Article

References (23)

1. Chien AI, Liao WH, Yang DM, Wang CT (2006) A domain directly C-terminal to the major homology region of human immunodeficiency type 1 capsid protein plays a crucial role in directing both virus assembly and incorporation of Gag-Pol. Virology 348:84-95
2. Huang XQ, Xu LS, Luo XM, Fan KN, Ji RY, Pei G, Chen KX, Jiang HL (2002) Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J Med Chem 45:333-343 (Pubitemid 34081128)
3. Huff JR (1991) HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem 34:2305-2314
4. Lebon F, Ledecq M (2000) Approaches to the design of effective HIV-1 protease inhibitors. Curr Med Chem 7:455-477 (Pubitemid 30396436)
5. Leung D, Abbenante G, Fairlie DP (2000) Protease inhibitors: current status and future prospects. J Med Chem 43:305-341 (Pubitemid 30102072)
6. Lunney EA, Hagen SE, Domagala JM, Humblet C, Kosinski J, Tait BD, Warmus JS, Wilson M, Ferguson D, Hupe D, Tummino PJ, Baldwin ET, Bhat TN, Liu B, Erickson JW (1994) A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. J Med Chem 37:2664-2677 (Pubitemid 24273458)
7. + T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol 165: 6437-6446
8. Meek TD (1992) Inhibitors of HIV-1 protease. J Enzym Inhib 6:65-98
9. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662 (Pubitemid 128590223)
10. Nashed NT, Louis JM, Sayer JM, Wondrak EM, Mora PT, Oroszlan S, Jerina DM (1989) Continuous spectrophotometric assay for retroviral protease of HIV-1 and AMV. Biochem Biophy Res Commun 163:1079-1085 (Pubitemid 19236959)
11. Peter M, Knudsen LB, Wiberg FC, Carr RD (1998) Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41:5150-5157 (Pubitemid 29016309)
12. Redshaw S (1994) Inhibitors of HIV proteinase. Exp Opin Invest Drugs 3:273-286
13. Romines KR, Chrusciel RA (1995) 4-Hydroxypyrones and related templates as nonpeptidic HIV protease inhibitors. Curr Med Chem 2:825-838 (Pubitemid 26024165)
14. Seshadri R, Pegg WJ, Israel M (1981) Reaction of halomethyl ketones with thiols and selenols: substitution vs reduction. J Org Chem 46:2596-2598
15. Skulnick HI, Johnson PD, Howe W, Tomich PK, Chong KT, Watenpaugh KD, Janakiraman MN, Hinshaw RR, Zipp GL, Ruwart MJ, Schwende FJ, Zhong WZ, Padbury GE, Dalga RJ, Shiou L, Possert PL, Rush BD, Wilkinson KF, Howard GM, Toth LN, Williams MG, Kakuk TJ, Cole SL, Zaya RM, Lovasz KD, Morris JK, Romines KR, Thaisrivongs S, Aristoff PA (1995) Structure-based design of sulfonamide-substituted nonpeptidic HIV protease inhibitors. J Med Chem 38:4968-4971 (Pubitemid 26018402)
16. Sun CL, Pang RF, Zhang H, Yang M (2005) Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors. Bioorg Med Chem Lett 15:3257-3262 (Pubitemid 40803482)
17. Tait BD, Domagala JM, Ellsworth EL, Gajda C, Hagen SE, Hamilton H, Vara Prasad JVN, Ferguson D, Graham N, Hupe D, Nouhan C, Tummino PJ, Humblet C, Lunney EA, Pavlovsky A, Rubin RJ, Baldwin ET, Bhat TN, Erickson JW, Gulnik S, Liu BS (1997) 4-Hydroxy-5, 6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. J Med Chem 40:3781-3792
18. Thaisrivongs S (1994) HIV protease inhibitors. Annu Rep Med Chem 29:133-144
19. Thaisrivongs S, Romero DL, Tommasi RA, Janakiraman MN, Strohbach JW, Turner SR, Biles C, Morge RR, Johnson PD, Aristoff PA, Tomich PK, Lynn JC, Horng MM, Chong KT, Hinshaw RR, Howe WJ, Finzel BC, Watenpaugh KD (1996) Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2- pyrones as effective, nonpeptidic inhibitors. J Med Chem 39:4630-4642 (Pubitemid 26382848)
20. Tummino PJ, Vara Prasad JVN, Ferguson D, Nouhan C, Graham N, Domagala JM, Ellsworth E, Gajda C, Hagen SE, Lunney EA, Para KS, Tait BD, Pavlovsky A, Erickson JW, Gracheck S, McQuade TJ, Hupe DJ (1996) Discovery and optimization of nonpeptide HIV-1 protease inhibitors. Bioorg Med Chem 4: 1401-1410 (Pubitemid 26319991)
21. Vara Prasad JVN, Boye FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Hagen SE, Markoski LJ, Steinbaugh BA, Tait BD, Humblet C, Lunney EA, Pavlovsky A, Rubin JR, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino PJ, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Saunders JM, VanderRoest S, Brodfuehrer J, Iyer K, Sinz M, Gulnik SV (1999) Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor. Bioorg Med Chem 7:2775-2800 (Pubitemid 30105851)
22. Wang TC, Lee KH, Chen YL, Liou SS (1998) Synthesis and anticancer evaluation of certain γ-aryloxymethyl-α-methylene-γ-phenyl- γ-butyrolactones. Bioorg Med Chem Lett 8:2773-2776
23. West ML, Fairlie DP (1995) Targeting HIV-1 PR: a test of drug-design methodologies. Trends Pharmacol Sci 16:67-75